Patent details

LUC00324 Product Name: Mavacamten or a pharmaceutically acceptable salt thereof

Basic Information

Publication number:
LUC00324
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP147389860
Legal Status:
Inactive
Application number:
LUC00324
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/23/1716
Marketing Authorization Type:
Marketing Authorization Date:
27/06/2023
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
30/11/2023
First Marketing Authorization date:
27/06/2023
Grant date:
02/02/2026
Activation date:
Publication date:
04/12/2023
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
27/06/2038
SPC Extension Expiration:
27/06/2038
Rejection date:
Withdrawal date:

Owner

From:
30/11/2023
 
 

Name:
MyoKardia, Inc.
Address:
333 Allerton Avenue, South San Francisco CA 94080, United States (US)

Agent

Name:
Dennemeyer & Associates S.A.
From:
30/11/2023
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2024/01
Publication date:
05/01/2024
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2026/04
Publication date:
03/03/2026
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
30/06/2034
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/11/2023 Summary of the product caracteristics 49
30/11/2023 Application Form 4
30/11/2023 Marketing authorization 3
30/11/2023 General Document 1
30/11/2023 MA publication 3
04/12/2023 Outgoing Correspondence 1
04/12/2023 Publication 1
02/02/2026 Publication 1
02/02/2026 Certificate 1
02/02/2026 Outgoing Correspondence 1